Joseph Raffaele: Can Improving Mitochondrial Quality in Immune Cells Alter Immune Aging Markers?
Joseph Raffaele, Physician-Scientist in Longevity Medicine, CEO of PhysioAge LLC, shared a post on LinkedIn about a recent article by Dominic Denk et al, published in Nature Aging:
”Mitochondria shape immune function over decades.
A recent human trial asked whether we could change this fate.
If we improve mitochondrial quality inside immune cells, can we alter immune aging markers in people?
As immune cells age, mitochondrial dysfunction accumulates.
Damaged mitochondria persist due to impaired mitophagy (damaged mitochondria cleanup).
Energy production declines, reactive oxygen species increase, and immune cells drift toward exhaustion and chronic inflammatory signaling.
In this study, 50 healthy middle-aged adults received 𝟏,𝟎𝟎𝟎 𝐦𝐠/𝐝𝐚𝐲 𝐨𝐟 𝐮𝐫𝐨𝐥𝐢𝐭𝐡𝐢𝐧 𝐀 𝐟𝐨𝐫 𝐟𝐨𝐮𝐫 𝐰𝐞𝐞𝐤𝐬, a compound shown to induce mitophagy and improve mitochondrial quality control.
Primary endpoints focused on phenotypic and metabolic remodeling of peripheral immune cells, rather than nonspecific clinical outcomes.
Participants receiving urolithin A showed:
- An expansion of naïve-like CD8 T cells
- Improved immune cell metabolic flexibility
- Increased mitochondrial biogenesis in key immune populations
Importantly, inflammatory cytokines and immune function were evaluated alongside cellular metabolism, allowing investigators to directly link mitochondrial quality with immune behavior rather than treating them as separate phenomena.
What makes this study important is the template it provides.
Aging biology advances when trials target a known mechanism, measure the right cell populations, and use human-relevant endpoints. This is the kind of evidence that moves geroscience from theory toward clinical practice.”
Title: Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial
Authors: Dominic Denk, Anurag Singh, Herbert G. Kasler, Davide D’Amico, Julia Rey, Lucía Alcober-Boquet, Johanna M. Gorol, Christoph Steup, Ritesh Tiwari, Ryan Kwok, Rafael J. Argüello, Julie Faitg, Kathrin Sprinzl, Stefan Zeuzem, Valentina Nekljudova, Sibylle Loibl, Eric Verdin, Chris Rinsch, Florian R. Greten
Read the Full Article on Nature Aging
Stay updated with Hemostasis Today.
-
May 30, 2026, 18:12Khokon Miah Akanda: FDA Approves a First-in-Class Hypertension Drug
-
May 30, 2026, 18:11Alessandro Perrella: It is Not Only about “How High the CRP is”, but “in Which Patient” We are Measuring That Value
-
May 30, 2026, 18:11Jasper van Grunsven: Grateful for Our Rare Disease Team and the Commitment That Drives Our Mission
-
May 30, 2026, 18:10Open Registration for the 2026 Thrombosis Canada Annual Education Conference – Thrombosis Canada
-
May 30, 2026, 18:09Peter Zdziarski: Approval Does Not Mean NovoSeven is 100% Effective or Risk-Free in GT
-
May 30, 2026, 17:07Deepak Yadav: A Privilege to Talk on ESUS at CREST Stroke Conclave 2026
-
May 30, 2026, 16:59Syed A Rizvi: Medical Scoring Systems – Small Numbers, Big Clinical Decisions
-
May 30, 2026, 16:53Timothy “Tim” Sheehan: BNY Wealth Joins the Fight Against Blood Disorders In Support of Hemophilia of Georgia
-
May 30, 2026, 16:51Nouf Bahri: Anticoagulation Initiation for New-Onset Atrial Fibrillation in Critical Illness